SCHOLAR - CNKI 学术搜索

Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?

来源：[J].PloS one(IF 3.73), 2016, Vol.11 (2), pp.e0148939PubMed

摘要：Not all new drug products are truly new. Some are the result of marginal innovation and incremental patenting of existing products, but in such a way that confers no major therapeutic improvement. This phenomenon, pejoratively known as "evergreening", can allow manufacturers to p...

全文获取

纸质馆藏

Could patents interfere with the development of a cardiovascular polypill?

作者：Beall Reed F , Schwalm Jon-David R ...

来源：[J].Journal of translational medicine(IF 3.459), 2016, Vol.14 (1), pp.242PubMed

摘要：The Wellcome Trust, the World Health Organization, and cardiologists have advocated for the idea of a "polypill" containing multiple cardiovascular drugs to be co-formulated into a single pill for over a decade. Some cardiologists have asserted that the drugs commonly considered ...

全文获取

纸质馆藏

Upstream solutions for price-gouging on critical generic medicines.

作者：Houston Adam R , Beall Reed F , Attaran Amir

来源：[J].Journal of pharmaceutical policy and practice, 2016, Vol.9, pp.15PubMed

摘要：Exorbitant price increases for critical off-patent medicines have received considerable media attention in recent months, leading to an investigation by the U.S. Senate. However, much of this attention has focused upon the companies that initiated the price increases, all of whom...

全文获取

纸质馆藏

The global intellectual property ecosystem for insulin and its public health implications: an observational study.

作者：Kaplan Warren A , Beall Reed F

来源：[J].Journal of pharmaceutical policy and practice, 2017, Vol.10, pp.3PubMed

摘要：Lack of access to insulin and poor health outcomes are issues for both low and high income countries. This has been accompanied by a shift from relatively inexpensive human insulin to its more expensive analogs, marketed by three to four main global players. Nonetheless, patent-b...

全文获取

纸质馆藏

Which patent and where? Why international patent transparency by companies is needed for medicines.

作者：Beall Reed F , Attaran Amir

来源：[J].Nature biotechnology, 2016, Vol.34 (9), pp.923-6PubMed

全文获取

纸质馆藏

Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.

作者：Beall Reed F , Kuhn Randall , Attaran Amir

来源：[J].Health affairs (Project Hope), 2015, Vol.34 (3), pp.493-501PubMed

摘要：Compulsory licensing has been widely suggested as a legal mechanism for bypassing patents to introduce lower-cost generic antiretrovirals for HIV/AIDS in developing countries. Previous studies found that compulsory licensing can reduce procurement prices for drugs, but it is unkn...

全文获取

纸质馆藏

Compulsory Licenses: The Authors Reply.

作者：Beall Reed F , Attaran Amir , Kuhn Randall

来源：[J].Health affairs (Project Hope), 2015, Vol.34 (6), pp.1068PubMed

全文获取

纸质馆藏

The time for pharmaceutical compulsory licensing has expired.

作者：Kuhn Randall , Beall Reed F

来源：[J].Nature Medicine, 2012, Vol.18 (8), pp.1168PubMed

全文获取

纸质馆藏